Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence
Lorenzo Federico, Brandon Malone, Simen Tennøe, Viktoriia Chaban, Julie Røkke Osen, Murat Gainullin, Eva Smorodina, Hassen Kared, Rahmad Akbar, Victor Greiff, Richard Stratford, Trevor Clancy, Ludvig Andre Munthe
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
Topicsvaccines and immunoinformatics approaches · SARS-CoV-2 and COVID-19 Research · Immunotherapy and Immune Responses
Text correction
In the published article, there were two errors: The “Material and methods” section preceded the “Introduction” section, and there was an inaccuracy in the wording of a sentence in the “Reagents” sub-section of “Material and methods”.
The “Introduction” now precedes the “Material and methods”, and a correction has been made to a sentence in “Materials and methods”, sub-section “Reagents”.
This sentence previously stated:
“Peptides were synthesized by GenScript (Piscataway, NJ, USA) at a purity ≥85%, and used at a final concentration of 1.5mg/mL each.”
The corrected sentence appears below:
“Peptides were synthesized by GenScript (Piscataway, NJ, USA) at a purity ≥85% and stored at a final concentration of 1.5mg/mL.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.